Phase 3 Enarodustat + CsA vs CsA for Newly Diagnosed TD-NSAA
Summary
A Phase 3 clinical trial (NCT07548671) has been registered to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in patients with newly diagnosed transfusion-dependent non-severe aplastic anemia (TD-NSAA). The study is evaluating two intervention arms: enarodustat with cyclosporine (CsA) as combination therapy versus cyclosporine alone. This trial registration provides healthcare providers and clinical investigators with information about an active Phase 3 study in the aplastic anemia treatment space.
“This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 3 clinical trial registration (NCT07548671) has been added to ClinicalTrials.gov for a study in transfusion-dependent non-severe aplastic anemia. The trial will evaluate enarodustat in combination with cyclosporine against cyclosporine monotherapy. For clinical investigators and healthcare providers involved in hematology or aplastic anemia research, this registration indicates an active Phase 3 study that may be relevant for patient referral considerations or competitive landscape awareness in the TD-NSAA treatment space.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA
Phase 3 NCT07548671 Kind: PHASE3 Apr 23, 2026
Abstract
This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).
Conditions: Transfusion-dependent Non-severe Aplastic Anemia
Interventions: Enarodustat, Cyclosporine (CsA)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.